

CMC STRATEGY FORUM

ADVANCING BIOPHARMACEUTICAL DEVELOPMENT

EUROPE 2024

KNOWLEDGE SHARING AND CAPACITY BUILDING

- *Don't overlook the regulatory tools we do have* – not all tools are available everywhere, and so we all must be change ambassadors.
- The AI-ML applications to be used for control and prediction of manufacturing are *expected to be covered by the PQS* rather than entered in the dossier, similar thoughts about GMP and PACMPS.
- *Internal advocacy is as important* as external advocacy .

CMC STRATEGY FORUM EUROPE 2024 BY THE NUMBERS



First-Time Attendees

75



Regulators Participation

28



Company Participation

69



Country Collaboration

20

Austria | Belgium | Canada | Denmark | Finland | France | Germany | Ireland | Israel | Italy | Japan | Netherlands | Norway | South Korea | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States